Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo.

Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov RR, Borrelli E, Caron MG.

J Neurosci. 2007 Jan 24;27(4):881-5.

2.

Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence.

Schwartz JC, Diaz J, Bordet R, Griffon N, Perachon S, Pilon C, Ridray S, Sokoloff P.

Brain Res Brain Res Rev. 1998 May;26(2-3):236-42. Review.

PMID:
9651537
3.

D3 dopamine receptor, behavioral sensitization, and psychosis.

Richtand NM, Woods SC, Berger SP, Strakowski SM.

Neurosci Biobehav Rev. 2001 Jul;25(5):427-43. Review.

PMID:
11566480
4.

The D3 dopamine receptor in cellular and organismal function.

Shafer RA, Levant B.

Psychopharmacology (Berl). 1998 Jan;135(1):1-16. Review.

PMID:
9489928
5.

The peripheral dopaminergic system: morphological analysis, functional and clinical applications.

Amenta F, Ricci A, Tayebati SK, Zaccheo D.

Ital J Anat Embryol. 2002 Jul-Sep;107(3):145-67. Review.

PMID:
12437142
6.

Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.

Wilson JM, Sanyal S, Van Tol HH.

Eur J Pharmacol. 1998 Jun 26;351(3):273-86. Review.

PMID:
9721018
7.

Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.

Jardemark K, Wadenberg ML, Grillner P, Svensson TH.

Curr Opin Investig Drugs. 2002 Jan;3(1):101-5. Review.

PMID:
12054059
8.

[Functional role of dopamine D3 receptor in schizophrenia].

Semba J.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Feb;24(1):3-11. Review. Japanese.

PMID:
15027325
9.

The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout').

Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT.

Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):925-64. Review.

PMID:
11383985
10.

The physiology, signaling, and pharmacology of dopamine receptors.

Beaulieu JM, Gainetdinov RR.

Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8. Review.

11.

Role of dopamine in the pathogenesis of hypertension.

Jose PA, Eisner GM, Felder RA.

Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S10-3. Review.

PMID:
10386248
12.

Psychosis pathways converge via D2high dopamine receptors.

Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T.

Synapse. 2006 Sep 15;60(4):319-46. Review.

PMID:
16786561
13.

The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches.

Griffon N, Sokoloff P, Diaz J, Lévesque D, Sautel F, Schwartz JC, Simon P, Costentin J, Garrido F, Mann A, et al.

Eur Neuropsychopharmacol. 1995;5 Suppl:3-9. Review.

PMID:
8775753
14.
15.

Dopamine receptors--physiological understanding to therapeutic intervention potential.

Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S.

Pharmacol Ther. 1999 Nov;84(2):133-56. Review.

PMID:
10596903
16.

Molecular neurobiology of dopaminergic receptors.

Sibley DR, Monsma FJ Jr, Shen Y.

Int Rev Neurobiol. 1993;35:391-415. Review.

PMID:
8463063
17.

Molecular characteristics of mammalian dopamine receptors.

Lachowicz JE, Sibley DR.

Pharmacol Toxicol. 1997 Sep;81(3):105-13. Review.

PMID:
9335067
18.

Dopamine D4 receptors and development of newer antipsychotic drugs.

Kulkarni SK, Ninan I.

Fundam Clin Pharmacol. 2000 Nov-Dec;14(6):529-39. Review.

PMID:
11206702
19.

Molecular dissection of dopamine receptor signaling.

Hiroi N, Martín AB, Grande C, Alberti I, Rivera A, Moratalla R.

J Chem Neuroanat. 2002 May;23(4):237-42. Review.

PMID:
12048106
20.

The dopaminergic system in hypertension.

Amenta F, Ricci A, Rossodivita I, Avola R, Tayebati SK.

Clin Exp Hypertens. 2001 Jan-Feb;23(1-2):15-24. Review.

PMID:
11270582

Supplemental Content

Support Center